Guilherme Vilhais, Diogo Alpuim Costa, Mário Fontes-Sousa, Pedro Casal Ribeiro, Filipa Martinho, Carolina Botelho de Sousa, Catarina Rodrigues Santos, Ida Negreiros, Ana Canastra, Paula Borralho, Ana Guia Pereira, Cristina Marçal, José Germano Sousa, Renata Chaleira, Júlio César Rocha, Conceição Calhau, Ana Faria
Locally advanced breast cancer poses significant challenges to the multidisciplinary team, in particular with hormone receptor (HR) positive, HER2-negative tumors that classically yield lower pathological complete responses with chemotherapy. The increasingly significant use of CDK 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) in different breast cancer settings has led to clinical trials focusing on this strategy as a primary treatment, with promising results. The impact of the microbiota on cancer, and vice-versa, is an emerging topic in oncology...
2024: Frontiers in Oncology